House passes drug price bill

Share this article:
The House of Representatives passed a bill Friday requiring government negotiation of drug prices for Medicare recipients by a vote of 255-170. The bill, promised as part of Speaker Nancy Pelosi’s “100 hours” agenda, replaced a much more ambitious plan scuttled because the Democrats wanted to avoid a rumble with pharmaceutical lobbyists, The Washington Post reported Friday. But the bill nonetheless would strike the “noninterference provision” that was part of the Medicare prescription drug benefit, which prohibits price controls, and mandates direct negotiations between Health and Human Services and drug companies over pricing. Should the bill pass through the Senate–-a prospect that seems unlikely, given Republican threats of a filibuster–-President Bush has promised to veto it. The bill’s chances in the Senate got a slight lift with the sign-on of Senate Finance Committee chairman Max Baucus, the centrist Montana Democrat, who said he believed the government should be able to negotiate prices for Medicare recipients in “discrete areas where our seniors need our help the most.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...